Investing.com -- TD Cowen upgraded SAP SE ADR (NYSE:SAP) stock to Buy from Hold and raised its price target to $305 from $240. Analysts at the bank cited SAP's resilient stock appreciation and ...

Investing.com -- TD Cowen downgraded STMicroelectronics (NYSE:STM) stock to Hold, citing increased cyclical headwinds in the semiconductor industry amid downstream inventory pressures. The firm ...

Investing.com -- TD Cowen downgraded Celsius Holdings (NASDAQ:CELH) to Hold and slashed its price target for the stock to $29 from $40 in a note Wednesday, citing slowing sales growth ...

TD Cowen upgraded Salesforce's (NYSE:CRM) rating to Buy from Hold and raised the price target to $400 from $380. Shares of Salesforce rose about 2% on Friday. Analysts led by Derrick Wood said ...

On Friday, TD Cowen initiated coverage on Expand Energy (NASDAQ:EXE) stock with a Hold rating and set a price target of $108.00. The firm's analysts noted that Expand Energy's shares have risen by ...

Investing.com -- TD Cowen upgraded SAP SE ADR (NYSE:SAP) stock to Buy from Hold and raised its price target to $305 from $240. Analysts at the bank cited SAP's resilient stock appreciation and growth ...

Celsius Holdings (NASDAQ:CELH) swung lower in early trading on Wednesday after TD Cowen downgraded the energy drink stock to a Hold rating after having it set at Buy. Notably, the firm's retail ...

Belfast is to undergo an environmental trial involving the analysis of 44 normal trees compared to a special “city tree.” City trees, also known as Robot Trees and Moss Walls, are large ...

TD Cowen analyst Moshe Orenbuch maintained a Buy rating on SLM (SLM – Research Report) today and set a price target of $33.00. The company’s shares closed yesterday at $29.30. According to ...

Investing.com -- TD Cowen downgraded STMicroelectronics (NYSE:STM) stock to Hold, citing increased cyclical headwinds in the semiconductor industry amid downstream inventory pressures. The firm also ...

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price target of $371.00. The company’s shares opened today at ...